In 1968, doctors told Greg Kindell that he had acute myeloid leukemia and he had just six weeks to live. Now he’s been cancer-free for 50 years.
drug
Oblato acquires all rights to glioblastoma drug from OMRF
Oblato, Inc., has acquired all rights from OMRF to OKN-007, an investigational drug for the treatment of a deadly form of brain cancer.
New OMRF grant will focus on autoimmune condition
The project will focus on comparing certain immune cells in patients with Sjögren’s to those of healthy controls.
Staying alive: Can an experimental OMRF drug stop Mike Schuster’s brain cancer?
As Mike Schuster nears the three-year anniversary of his diagnosis with glioblastoma, he’s already doubled the life expectancy for patients with the deadly cancer.
New hope in the fight against sickle cell disease
For Mary Long, the answer to her pain may, literally, be right around the corner.
OMRF enters into a license agreement with Shanghai RAAS Blood Products
OMRF has entered a license agreement with Shanghai RAAS Blood Products for development of novel hemophilia treatment.
